Roger Longman speaks about drug pricing in the current environment, and how payers, pharma, and providers must adapt to ever-changing models of reimbursement.
read full article ›Learn why are we are seeing increasing numbers of value-based deals in the industry, how they are structured and when they make sense.
read full article ›A new, structured approach to bringing value-based reimbursement models into the mainstream is outlined, thus transforming reimbursement and fueling the shift from volume to value.
read full article ›The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and commercial launches in 2015, but only a handful of approvals.
read full article ›That Apple ($APPL) watch you are wearing may allow you to text and listen to music, and it can track your activity. But it may also be conducting a postmarket study that will help cut the price of some of your prescription drugs in the future.
read full article ›Gilead Sciences Inc. and AbbVie Inc. continue to vie for preferred coverage of their HCV drugs in the U.S. private payer market, and Gilead is out to an early lead when it comes to total lives covered. But much of the population is still up for grabs, and the real victor in share of lives could be determined by how the U.S. Department of Veterans Affairs and Medicaid plans respond.
read full article ›How Sanofi should think about pricing/rebates for first-to-market PCSK9 inhibitor
read full article ›Hepatitis C drugs may have provided the spark, but cost-pressured payors, empowered consumers, and at-risk providers are adding fuel to the drug pricing fire. The game may be up for pharma firms that try to push prices out of line with perceived value, potential patient volumes, and affordability.
read full article ›Memorial Sloan Kettering’s Peter Bach unveils a web-based drug pricing tool that uses several value measurements, including R&D investment and novelty, to identify the appropriate price for cancer drugs.
read full article ›As prices for specialty drugs like oncologics soar, outrage is mounting over the cost of the new therapies, prompting a debate about their value. Could any of this spill over to medical devices?
read full article ›